Where the Blood Goes
Sixty-One Diseases, One System
Two drugs earned $71 billion in 2025. Semaglutide and tirzepatide. More than double OpenAI and Anthropic combined. Tirzepatide is now the best-selling pharmaceutical on earth, and both did it, reaching under 2% of the people who qualify.
In January 2025, Washington University followed 215,970 patients on these drugs, matched against controls, across 175 conditions. Risk fell on 42 of them. It rose on 19.
Sixty-one conditions moved. One molecule.
They were never sixty-one conditions.
A hormone is a chemical messenger that travels in the blood, which means it reaches every tissue the blood reaches. Nothing about the molecule changes between tissues. Only the cell receiving it. GLP-1 receptors sit on the pancreas, in the hypothalamus, on the stomach lining, and in the brain’s reward circuitry. The drug does not report to a department. It goes everywhere at once.
Medicine is not built that way. Medicine is built by organ. Endocrinology, cardiology, nephrology, pulmonology, hepatology, addiction. Separate boards, separate journals, separate clinics, separate billing codes. That structure came from how you train a doctor and how you pay one. It did not come from the body.
The indication cascade reads like discovery. Diabetes, then obesity in 2021, then a 20% cut in cardiovascular events, then 24% on kidney outcomes, then sleep apnea, then liver disease. Every trial surfaces an effect nobody designed for, and the next molecule is already on the gray market for $25 a dose.
The day Novo said the kidney trial had been stopped early for benefit, DaVita and Fresenius each fell about 17%. Dialysis runs about 1% of the entire federal budget, two companies hold most of the market, and three-quarters of kidney failure cases trace back to diabetes and high blood pressure. A drug that slows kidney decline shrinks the population those companies were built to serve. Nobody had to win that argument. The stock settled it in an afternoon.
Walmart’s U.S. CEO can see GLP-1 users buying smaller baskets. Nestlé sells a frozen meal line designed for them.
Addiction is on the list of 42, and it is the only one there with no incumbent to reprice. Thirty-six million Americans, no dialysis chain, no device franchise, nothing to short. Nobody’s stock moved on that one.
So the thing coming down is not obesity. It is a specialty as a unit of medicine. An org chart drawn around organs and paid by code, meeting a molecule that does not recognize any of it.
We already knew the body was one system. Food said it first. Evolution made is so, without filing any patents.